Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis

Ferrao Blanco, M. N.; Domenech Garcia, H.; Legeai-Mallet, L.; van Osch, G.J.V.M.

doi:10.1016/j.joca.2021.07.003

Tyrosine kinases regulate chondrocyte hypertrophy

Title

Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis

Author

Ferrao Blanco, M. N. (Erasmus MC)
Domenech Garcia, H. (Erasmus MC)
Legeai-Mallet, L. (Université de Paris)
van Osch, G.J.V.M. (TU Delft Biomaterials & Tissue Biomechanics; Erasmus MC)

Date

2021

Abstract

Osteoarthritis (OA) is a major health problem worldwide that affects the joints and causes severe disability. It is characterized by pain and low-grade inflammation. However, the exact pathogenesis remains unknown and the therapeutic options are limited. In OA articular chondrocytes undergo a phenotypic transition becoming hypertrophic, which leads to cartilage damage, aggravating the disease. Therefore, a therapeutic agent inhibiting hypertrophy would be a promising disease-modifying drug. The therapeutic use of tyrosine kinase inhibitors has been mainly focused on oncology, but the Food and Drug Administration (FDA) approval of the Janus kinase inhibitor Tofacitinib in Rheumatoid Arthritis has broadened the applicability of these compounds to other diseases. Interestingly, tyrosine kinases have been associated with chondrocyte hypertrophy. In this review, we discuss the experimental evidence that implicates specific tyrosine kinases in signaling pathways promoting chondrocyte hypertrophy, highlighting their potential as therapeutic targets for OA.

Subject

Chondrocyte hypertrophy
Disease modifying OA drugs
Tyrosine kinases

To reference this document use:

http://resolver.tudelft.nl/uuid:4dcae5df-3e24-4950-a80c-2ce8c52602f4

DOI

https://doi.org/10.1016/j.joca.2021.07.003

ISSN

1063-4584

Source

Osteoarthritis and Cartilage, 29 (10), 1389-1398

Part of collection

Institutional Repository